Ekso Bionics Holdings, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:EKSO)

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Market Capitalization 28.0446 M
Employee 55
Founded 2005
CEO Scott Davis
Website www.eksobionics.com
Headquarter Nevada, United States
FIGI BBG002Z0NKK4
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

28.04 M Market capitalization

Price to earnings ratio

-1.76

Price to sales ratio

1.64

Ekso Bionics Holdings Inc

Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk. Ekso Bionics currently focuses in the health and industrial sectors. The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community.